Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929901 | 0.89 | NOD1 (0.42) | TERTPTGS1GSTK1NOD1ENPEP | |
| SCHEMBL29429287 | 0.89 | ECE1 (0.51) | CA2TERTPTGS1GSTK1NOD1 | |
| SCHEMBL30997361 | 0.86 | FNTA (0.44) | — | |
| SCHEMBL30662551 | 0.85 | CA2 (0.47) | CA2CA4EPHX2PTGS1GSTK1 | |
| SCHEMBL29351781 | 0.85 | MME (0.47) | TERTPTGS1GSTK1NOD1MME | |
| SCHEMBL31402734 | 0.85 | NOD1 (0.46) | PTGS1GSTK1NOD1ENPEPECE1 | |
| SCHEMBL29544382 | 0.85 | MME (0.44) | CA2CA4EPHX2PTGS1GSTK1 | |
| SCHEMBL30662550 | 0.84 | FOLH1 (0.50) | PTGS1GSTK1NOD1 | |
| SCHEMBL29590916 | 0.84 | ALDH1A1 (0.51) | TERTMME | |
| SCHEMBL29373113 | 0.84 | ACE (0.53) | TERTPTGS1GSTK1NOD1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857631-B2 | Protection and delivery of multiple therapeutic proteins | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-01-02 | — | — | US | claimed |
| US-20220249672-A1 | Protection and Delivery of Multiple Therapeutic Proteins | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | claimed |
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| US-11857631-B2 | Protection and delivery of multiple therapeutic proteins | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-11779647-B2 | Complex coacervate for controlled release and related methods | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220249672-A1 | Protection and Delivery of Multiple Therapeutic Proteins | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| US-11298423-B2 | Protection and delivery of multiple therapeutic proteins | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | CA2 4388/4885CA4 3285/4885TERT 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.